Terns Pharmaceuticals, Inc. (NasdaqGM: TERN)
Health Care · Pharmaceuticals · US
$—
— today · — 1Y
Terns Pharmaceuticals, Inc. (NasdaqGM: TERN) operates in the Pharmaceuticals industry within the Health Care sector.
trading between 6.65 and 53.19.
Tweenvest scores Terns Pharmaceuticals, Inc. across four factors: quality 31/100. Its strongest factor is quality.
TERN price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- —
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -1.03
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $53.19
- 52-week low
- $6.65
- Avg volume (3M)
- —
- Shares outstanding
- —
- Employees
- 59
- Next earnings
- —
About Terns Pharmaceuticals, Inc.
Terns Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to advancing novel small-molecule treatments. Its primary focus lies in developing both standalone agents and combination therapies to address non-alcoholic steatohepatitis (NASH) and obesity. The company's pipeline includes several key drug candidates: TERN-101, a farnesoid X receptor agonist distinguished by its liver-specific distribution and non-bile acid properties, is presently undergoing Phase IIa clinical trials for NASH. TERN-201, a vascular adhesion protein-1 inhibitor, is in Phase Ib clinical studies, also targeting NASH. Terns is also progressing TERN-501, a thyroid hormone receptor beta agonist engineered for improved liver targeting and metabolic resilience, through Phase I clinical trials for NASH. Furthermore, the company is advancing TERN-601, an oral small-molecule Glucagon-Like Peptide-1 receptor agonist program, intended for the management of NASH and various metabolic conditions, including obesity. Established in 2016, Terns Pharmaceuticals maintains its corporate headquarters in Foster City, California.
- ISIN
- US8808811074
- Founded
- 2016
- Listed since
- Feb 5, 2021
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.11T | $1,247.58 | +0.05% |
| Johnson & JohnsonNYSE: JNJ | $658.00B | $271.39 | -0.60% |
| Merck & Co., Inc.NYSE: MRK | $371.70B | $151.23 | +0.38% |
| Roche Holding AGSWX: ROP | $368.80B | CHF371.10 | +0.19% |
| Novartis AGSWX: NOVN | $300.52B | CHF126.76 | -0.52% |
| AstraZeneca PLCLSE: AZN | $256.25B | £121.32 | +0.18% |
| Novo Nordisk A/SCPSE: NOVO B | $206.64B | Dkr299.25 | -0.53% |
| Pfizer Inc.NYSE: PFE | $159.42B | $28.02 | +0.18% |
Figures last refreshed Aug 18, 2026.